We are developing cytokine fusion molecules, especially antibody-cytokine prodrug fusion molecules, which selectively modulate a subset of immune cells in the tumor microenvironment. Of particular interest are cancers of the digestive tract, such as gastric, esophageal, colorectal, and liver cancers. We believe modulating immune cells has the potential to treat other cancers as well.
We are also developing cytokine fusion molecules for addressing autoimmune diseases and inflammation disorders. Our prodrug candidates are focused on selectively stimulating specific subsets of immune cells to treat diseases such as lupus, inflammatory bowel disease (IBD), and Type 1 diabetes.
ASKG712 is a bifunctional molecule that targets vascular endothelial growth factor (VEGF) and Ang-2 to address specific needs in ophthalmology, including wet age-related macular degeneration (wAMD) and diabetic macular edema (DME ).
* Biosimilar program, out-licensed
** Masked or prodrug